Duan Hanying, Zhu Lijun, Li Min, Zhang Xinyue, Zhang Beilin, Fang Shaokuan
Department of Neurology, Neuroscience Centre, The First Hospital of Jilin University, Changchun, China.
China-Japan Union Hospital of Jilin University, Changchun, China.
Front Pharmacol. 2022 Sep 6;13:949823. doi: 10.3389/fphar.2022.949823. eCollection 2022.
There are several selective serotonin reuptake inhibitor (SSRI) antidepressants currently used to treat binge eating disorder (BED), but the efficacy and acceptability of these antidepressants are still controversial. Therefore, we designed a network meta-analysis (NMA) to compare the efficacy and acceptability of different SSRI antidepressants for the treatment of BED. Four databases including PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched for the eligible randomized controlled trials (RCTs) for the treatment of patients with BED. The analysis was performed with Stata16 software. 9 RCTs were included in this NMA. The results of the study showed that compared with placebo, sertraline and fluoxetine could significantly reduce the frequency of binge eating. Fluoxetine was shown to be the drug with the greatest reduction in Hamilton Rating Scale for Depression (HAMD) score. Besides, all SSRI antidepressants were ineffective in losing weight. In addition, all the investigated antidepressants were found to be well acceptable in regards to the acceptability reflected by the dropout rate. As far as both efficacy and acceptability were concerned, fluoxetine might be the best choice.
目前有几种选择性5-羟色胺再摄取抑制剂（SSRI）类抗抑郁药用于治疗暴饮暴食症（BED），但这些抗抑郁药的疗效和可接受性仍存在争议。因此，我们设计了一项网状Meta分析（NMA），以比较不同SSRI类抗抑郁药治疗BED的疗效和可接受性。系统检索了包括PubMed、Embase、Cochrane图书馆和Web of Science在内的四个数据库，以查找治疗BED患者的符合条件的随机对照试验（RCT）。使用Stata16软件进行分析。该NMA纳入了9项RCT。研究结果表明，与安慰剂相比，舍曲林和氟西汀可显著降低暴饮暴食的频率。氟西汀被证明是使汉密尔顿抑郁量表（HAMD）评分降低幅度最大的药物。此外，所有SSRI类抗抑郁药在减肥方面均无效。此外，就脱落率所反映的可接受性而言，所有被研究的抗抑郁药都具有良好的可接受性。就疗效和可接受性而言，氟西汀可能是最佳选择。
